Services Stocks' Research Reports Released on XpresSpa, Nutrisystem, Myriad Genetics, and QIAGEN
NEW YORK, April 4, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on XSPA, NTRI, MYGN, and QGEN which can be accessed for free by signing up to www.wallstequities.com/registration. Ahead of today's trading session, WallStEquities.com draws investors' attention to the Services sector, which produces intangible goods, more precisely services instead of goods. Lined up for review this morning are the following stocks: XpresSpa Group Inc. (NASDAQ: XSPA), Nutrisystem Inc. (NASDAQ: NTRI), Myriad Genetics Inc. (NASDAQ: MYGN), and QIAGEN N.V. (NYSE: QGEN). All you have to do is sign up today for this free limited time offer by clicking the link below.
www.wallstequities.com/registration
XpresSpa Group
New York-based XpresSpa Group Inc.'s stock finished Tuesday's session 3.54% lower at $0.61 with a total trading volume of 122,035 shares. The stock is trading below their 50-day moving average by 35.28%. Shares of the Company, which operates as a health and wellness company in the US and internationally, have a Relative Strength Index (RSI) of 24.35.
On March 15th, 2018, XpresSpa Group announced that its wholly owned subsidiary, XpresSpa, launched a new website and ecommerce platform. The new website will offer many XpresSpa products, featuring a full line of travel accessories manufactured through the Company's partnership with Capelli New York, global designers, and manufactures of on-trend, private label, and branded products. Get the full research report on XSPA for free by clicking below at:
www.wallstequities.com/registration/?symbol=XSPA
Nutrisystem
Shares in Fort Washington, Pennsylvania headquartered Nutrisystem Inc. ended at $26.95, down 1.28% from the last trading session. The stock recorded a trading volume of 694,247 shares. The Company's shares are trading 26.78% below their 50-day moving average. Moreover, shares of Nutrisystem, which together with its subsidiaries, provides weight management products and services for women and men in the US, have an RSI of 27.86.
On March 20th, 2018, research firm Argus downgraded the Company's stock rating from 'Buy' to 'Hold'.
On April 02nd, 2018, Nutrisystem announced that it will report its Q1 2018 financial results after the market close on April 30th, 2018. The Company will hold a conference call with the investment community at 5:00 p.m. ET that same day. A live webcast of the conference call will be available under the Investor Relations section of the Company's website. Gain free access to the research report on NTRI at:
www.wallstequities.com/registration/?symbol=NTRI
Myriad Genetics
Salt Lake City, Utah headquartered Myriad Genetics Inc.'s stock ended yesterday's session 1.37% higher at $29.55. A total volume of 741,344 shares was traded, which was above their three months average volume of 733,840 shares. The Company's shares have advanced 53.91% over the past year. The stock is trading 6.50% below its 200-day moving average. Additionally, shares of Myriad Genetics, which focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide, have an RSI of 41.22.
On March 21st, 2018, research firm Morgan Stanley upgraded the Company's stock rating from 'Underweight' to 'Equal-Weight'.
On April 02nd, 2018, Myriad Genetic Laboratories, Inc., a wholly owned subsidiary of Myriad Genetics, announced that the Japanese Ministry of Health, Labor, and Welfare has granted manufacturing and marketing approval for the Company's BRACAnalysis® Diagnostic System to be used as a companion diagnostic with the PARP inhibitor, Lynparza. Lynparza is marketed by AstraZeneca and Merck, known as MSD outside the US and Canada. Signing up today on Wall St. Equities will give you access to the latest report on MYGN at:
www.wallstequities.com/registration/?symbol=MYGN
QIAGEN
On Tuesday, shares in Venlo, the Netherlands headquartered QIAGEN N.V. recorded a trading volume of 807,573 shares. The stock finished 0.32% lower at $31.49. The Company's shares have advanced 1.81% in the previous three months and 8.70% over the past year. The stock is trading below its 200-day moving average by 3.96%. Furthermore, shares of QIAGEN, which provides sample to insight solutions that transform biological materials into molecular insights worldwide, have an RSI of 34.14.
On March 12th, 2018, QIAGEN and Natera, Inc. announced a partnership to develop cutting-edge, cell-free DNA assays for use on the former's GeneReader NGS System. These cell-free DNA assays will now be developed for use on the GeneReader NGS System, the first fully integrated Sample to Insight NGS solution, and designed to enable these type of tests, including prenatal screening, for hospitals and laboratories globally. Register now for today's free coverage on QGEN at:
www.wallstequities.com/registration/?symbol=QGEN
--
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
https://wallstequities.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: +21-32 044 483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Wall St. Equities
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article